alpha-aminopyridine has been researched along with Fatty Liver, Nonalcoholic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Birnbaumer, L; Chen, Z; Duan, J; Duan, R; Feng, Q; Gu, S; He, B; Jiang, J; Lv, K; Qin, Y; Wang, Z; Yang, C; Yang, S; Yang, Y; Zhang, L; Zhao, R | 1 |
| Feng, X; Fu, J; Fu, Q; He, H; Hu, Y; Huang, K; Li, L; Peng, J; Shen, A; Tao, X; Xu, R; Yang, X; Yu, X; Zhang, C; Zhang, L | 1 |
| He, Q; Tang, R; Wang, W; Wu, Q; Xia, X; Yao, K; Zeng, J; Zou, X | 2 |
| Ahmadian, M; Ajluni, N; Butz, L; Chenevert, TL; Downes, M; Evans, RM; Gomez, AV; Hench, R; Horowitz, JF; Jain, M; Korytnaya, E; Lehmann, K; Liddle, C; Meral, R; Neidert, AH; Oral, EA; Poirier, B; Reilly, SM; Rus, D; Saltiel, AR; Yu, R; Zhao, P | 1 |
| Baeck, C; Federici, M; Kahles, F; Kappel, B; Lebherz, C; Lehrke, M; Marx, N; Möllmann, J; Tacke, F; Werner, C | 1 |
1 trial(s) available for alpha-aminopyridine and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Inhibition of IKKɛ and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes.
Topics: Aged; Aminopyridines; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Energy Metabolism; Female; Glycated Hemoglobin; Humans; I-kappa B Kinase; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2017 |
5 other study(ies) available for alpha-aminopyridine and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice.
Topics: Aminopyridines; Animals; Benzimidazoles; Biopsy; Coenzyme A Ligases; Diet, High-Fat; Disease Models, Animal; Fatty Acids; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver; Mice; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction | 2022 |
Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast.
Topics: Aminopyridines; Animals; Aorta; Becaplermin; Benzamides; CD36 Antigens; Cell Proliferation; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Hepatocytes; Hypertension; Insulin; Liver; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Myocytes, Smooth Muscle; Nanoparticles; Non-alcoholic Fatty Liver Disease; Phosphodiesterase 4 Inhibitors; Polymers; RNA, Small Interfering; Sirtuin 1; Transforming Growth Factor beta1 | 2022 |
Amlexanox reversed non-alcoholic fatty liver disease through IKKε inhibition of hepatic stellate cell.
Topics: Actins; Aminopyridines; Animals; Body Weight; Energy Metabolism; Gene Expression; Glucose; Hepatic Stellate Cells; Hepatocytes; I-kappa B Kinase; Insulin; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Signal Transduction | 2019 |
Long-term subcutaneous injection of lipopolysaccharides and high-fat diet induced non-alcoholic fatty liver disease through IKKε/ NF-κB signaling.
Topics: Aminopyridines; Animals; Diet, High-Fat; Disease Models, Animal; Gene Expression; I-kappa B Kinase; Injections, Subcutaneous; Lipid Metabolism; Lipopolysaccharides; Liver; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Non-alcoholic Fatty Liver Disease; Protein Kinase Inhibitors; Signal Transduction | 2020 |
The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism.
Topics: Aminopyridines; Animals; Benzamides; Cyclic AMP-Dependent Protein Kinases; Cyclopropanes; Diet, High-Fat; Energy Metabolism; Glucose; Insulin Resistance; Liver; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Signal Transduction; Weight Gain | 2017 |